AC Immune SA (ACIU)

AC Immune Cash Flow Statement

Financials in millions CHF. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-54.58	-54.23	-70.75	-73	-61.92	45.44
Depreciation & Amortization	2.2	2.22	2.36	2.41	1.97	1.69
Share-Based Compensation	4.78	4.37	3.33	4.13	4.09	2.83
Other Operating Activities	4.25	-13.17	-8.1	1.25	-3.38	5.26
Operating Cash Flow	-43.35	-60.83	-73.16	-65.22	-59.25	55.23
Capital Expenditures	-0.85	-0.8	-1.24	-2.64	-1.64	-1.89
Change in Investments	0.19	66.45	25	-51	30	-65
Other Investing Activities	-0.05	-	0	-0.03	-0.03	-
Investing Cash Flow	-0.72	65.65	23.76	-53.66	28.33	-66.89
Share Issuance / Repurchase	43.81	43.8	-0	17.8	0.14	-0.44
Debt Issued / Paid	-0.58	-0.55	-0.57	22.95	-0.95	50.06
Other Financing Activities	-0.52	-	-0.78	-	-	-
Financing Cash Flow	42.7	43.25	-1.35	40.75	-0.8	49.62
Exchange Rate Effect	0.17	-1.58	0.52	-0.07	-0.7	-0.83
Net Cash Flow	-0.6	48.49	-51.15	-78.61	-31.99	37.95
Free Cash Flow	-44.2	-61.63	-74.4	-67.85	-60.89	53.34
Free Cash Flow Margin	-298.66%	-416.38%	-1890.67%	-	-394.59%	48.29%
Free Cash Flow Per Share	-0.45	-0.73	-0.88	-0.93	-0.85	0.79

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).